ZhuZhou QianJin Pharmaceutical Co.,Ltd (SHA:600479)
China · Delayed Price · Currency is CNY 10.51
+0.03 (0.29%)
Feb 4, 2026, 1:14 PM CST
SHA:600479 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,578 | 3,574 | 3,721 | 3,955 | 3,599 | 3,586 |
Other Revenue | 55.71 | 55.71 | 77.38 | 71.35 | 65.12 | 40.7 |
| 3,633 | 3,630 | 3,798 | 4,026 | 3,664 | 3,627 | |
Revenue Growth (YoY) | -2.70% | -4.44% | -5.66% | 9.89% | 1.02% | 2.89% |
Cost of Revenue | 1,849 | 1,951 | 2,051 | 2,296 | 2,038 | 2,038 |
Gross Profit | 1,784 | 1,679 | 1,748 | 1,731 | 1,626 | 1,589 |
Selling, General & Admin | 1,222 | 1,138 | 1,167 | 1,172 | 1,128 | 1,109 |
Research & Development | 220.71 | 220.2 | 149.07 | 113.82 | 108.72 | 104.06 |
Other Operating Expenses | 31.4 | 25.8 | 38 | 37.93 | 35.11 | 34.68 |
Operating Expenses | 1,481 | 1,390 | 1,372 | 1,326 | 1,271 | 1,250 |
Operating Income | 302.99 | 288.57 | 376.42 | 404.85 | 354.6 | 338.86 |
Interest Expense | -0.16 | -1.11 | -1.67 | -2.21 | -2.11 | -2.25 |
Interest & Investment Income | 90.51 | 51.11 | 70.19 | 30.7 | 33.64 | 52.46 |
Other Non Operating Income (Expenses) | -9.55 | -6.6 | -6.05 | -4.26 | -2.93 | 1.6 |
EBT Excluding Unusual Items | 383.78 | 331.97 | 438.9 | 429.08 | 383.19 | 390.67 |
Gain (Loss) on Sale of Investments | 3.18 | 0.63 | -1.6 | -1.3 | 4.72 | 2.08 |
Gain (Loss) on Sale of Assets | 1.5 | 0.05 | -0.94 | 0.17 | 33.11 | 5.32 |
Asset Writedown | -2.91 | -4.24 | - | - | - | - |
Other Unusual Items | 6.89 | 6.89 | 24.06 | 17.85 | 12.4 | 26.52 |
Pretax Income | 392.45 | 335.31 | 460.42 | 445.81 | 433.42 | 424.58 |
Income Tax Expense | 44.97 | 32.7 | 65.4 | 58.67 | 58.68 | 64.38 |
Earnings From Continuing Operations | 347.48 | 302.61 | 395.02 | 387.15 | 374.74 | 360.21 |
Minority Interest in Earnings | -97.44 | -71.85 | -74.61 | -84.64 | -72.68 | -63.14 |
Net Income | 250.04 | 230.76 | 320.41 | 302.51 | 302.06 | 297.07 |
Net Income to Common | 250.04 | 230.76 | 320.41 | 302.51 | 302.06 | 297.07 |
Net Income Growth | -14.25% | -27.98% | 5.92% | 0.15% | 1.68% | 0.94% |
Shares Outstanding (Basic) | 409 | 414 | 423 | 428 | 418 | 419 |
Shares Outstanding (Diluted) | 409 | 414 | 423 | 428 | 418 | 419 |
Shares Change (YoY) | -2.16% | -2.11% | -1.31% | 2.30% | -0.01% | -0.00% |
EPS (Basic) | 0.61 | 0.56 | 0.76 | 0.71 | 0.72 | 0.71 |
EPS (Diluted) | 0.61 | 0.56 | 0.76 | 0.71 | 0.72 | 0.71 |
EPS Growth | -12.35% | -26.43% | 7.32% | -2.11% | 1.69% | 0.94% |
Free Cash Flow | 518.97 | 351.45 | 399.13 | 699.04 | 413.69 | 445.14 |
Free Cash Flow Per Share | 1.27 | 0.85 | 0.94 | 1.63 | 0.99 | 1.06 |
Dividend Per Share | 0.360 | 0.360 | 0.350 | 0.350 | 0.600 | 1.000 |
Dividend Growth | 2.86% | 2.86% | - | -41.67% | -40.00% | 100.00% |
Gross Margin | 49.11% | 46.25% | 46.02% | 42.98% | 44.38% | 43.81% |
Operating Margin | 8.34% | 7.95% | 9.91% | 10.05% | 9.68% | 9.34% |
Profit Margin | 6.88% | 6.36% | 8.43% | 7.51% | 8.24% | 8.19% |
Free Cash Flow Margin | 14.28% | 9.68% | 10.51% | 17.36% | 11.29% | 12.27% |
EBITDA | 375.77 | 364.76 | 457.17 | 473.88 | 418.84 | 399.75 |
EBITDA Margin | 10.34% | 10.05% | 12.04% | 11.77% | 11.43% | 11.02% |
D&A For EBITDA | 72.78 | 76.19 | 80.74 | 69.03 | 64.24 | 60.89 |
EBIT | 302.99 | 288.57 | 376.42 | 404.85 | 354.6 | 338.86 |
EBIT Margin | 8.34% | 7.95% | 9.91% | 10.05% | 9.68% | 9.34% |
Effective Tax Rate | 11.46% | 9.75% | 14.21% | 13.16% | 13.54% | 15.16% |
Revenue as Reported | 3,633 | 3,630 | 3,798 | 4,026 | 3,664 | 3,627 |
Advertising Expenses | - | 12.82 | 10.56 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.